Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 9/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 9/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20007955 | 0.94 | CYP2D6 (0.44) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL29341677 | 0.90 | CYP2D6 (0.46) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL18848901 | 0.85 | LMNA (0.45) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL25015103 | 0.83 | LMNA (0.46) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL18896609 | 0.83 | LMNA (0.43) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL21776108 | 0.82 | LMNA (0.42) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL18194973 | 0.81 | CYP2D6 (0.36) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL21451536 | 0.81 | LMNA (0.41) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL1096010 | 0.80 | LMNA (0.55) | CYP2D6LMNACHRM2ADRA2ATSHR | |
| SCHEMBL24713735 | 0.79 | LMNA (0.36) | CYP2D6LMNACHRM2ADRA2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081310-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024006544-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023147042-A2 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING CNS DISORDERS | SIGILON THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023076620-A1 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| US-20230003706-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | SIGILON THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | CYP2D6 3360/4885LMNA 3474/4885CHRM2 4830/4885 |
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | CDK8, CDK7, CDK18 | CYP2D6 1202/4885LMNA 963/4885CHRM2 3804/4885 |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | CYP2D6 3360/4885LMNA 3474/4885CHRM2 4830/4885 |
| US-20230003706-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | FN1, MFAP1, FIBP | CYP2D6 4245/4885LMNA 158/4885CHRM2 1751/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | CYP2D6 4015/4885LMNA 95/4885CHRM2 3131/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP2D6 1147/4885LMNA 1824/4885CHRM2 68/4885 |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | F7, F13B, F9 | CYP2D6 2919/4885LMNA 912/4885CHRM2 4763/4885 |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CYP2D6 3240/4885LMNA 3480/4885CHRM2 4850/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CYP2D6 3240/4885LMNA 3480/4885CHRM2 4850/4885 |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | CYP2D6 1202/4885LMNA 963/4885CHRM2 3804/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CYP2D6 3240/4885LMNA 3480/4885CHRM2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.